MAPT and brain disorder: The measured molecule may be a well-known biomarker (e.g., amyloid beta, amyloid precursor protein, tau, synuclein, and neuron-specific enolase) or a new biomarker discovered using the above-described BDEV-based brain disease diagnosis strategy.